- Home
- MDGL vs HST Comparison
MDGL vs HST Comparison
Compare MDGL & HST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | HST |
|---|---|---|
| Founded | 2011 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 13.1B |
| IPO Year | 2005 | 1998 |
Fundamental Metrics
Financial Performance| Metric | MDGL | HST |
|---|---|---|
| Price | $520.47 | $21.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $674.45 | $20.54 |
| AVG Volume (30 Days) | 355.7K | ★ 7.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.56% |
| EPS Growth | ★ 41.32 | 11.11 |
| EPS | N/A | ★ 1.10 |
| Revenue | $180,133,000.00 | ★ $5,387,000,000.00 |
| Revenue This Year | $58.39 | $0.10 |
| Revenue Next Year | $48.55 | $1.09 |
| P/E Ratio | ★ N/A | $18.95 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $265.00 | $13.68 |
| 52 Week High | $615.00 | $21.55 |
Technical Indicators
Market Signals| Indicator | MDGL | HST |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 63.66 |
| Support Level | $503.93 | $18.59 |
| Resistance Level | $539.17 | N/A |
| Average True Range (ATR) | 16.69 | 0.45 |
| MACD | -1.95 | 0.11 |
| Stochastic Oscillator | 38.54 | 79.50 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About HST Host Hotels & Resorts Inc.
Host Hotels & Resorts owns 80 predominantly urban and resort upper-upscale and luxury hotel properties representing nearly 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.